Aura Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Aura Biosciences, Inc. on June 11, 2026. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol AURA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals. A total of 64,199,778 shares were entitled to vote, with 52,784,744 shares present or represented by proxy.
- Proposal 1: Election of Directors
- David Johnson: Elected as a Class II director. Received 34,542,193 votes for, 6,628,297 votes withheld, and 11,614,254 broker non-votes.
- Teresa Marie Bitetti: Elected as a Class II director. Received 40,526,332 votes for, 644,158 votes withheld, and 11,614,254 broker non-votes.
- Proposal 2: Ratification of Independent Registered Accounting Firm
- Stockholders ratified the appointment of Ernst & Young LLP for the fiscal year ending December 31, 2026.
- Votes For: 52,752,601
- Votes Against: 17,348
- Abstentions: 14,795
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the new Board composition following the election of David Johnson and Teresa Marie Bitetti.
- Verification of the high level of support for the ratification of Ernst & Young LLP (over 99% of votes cast were in favor).
- Review of the definitive proxy statement filed on April 20, 2026, for detailed background on the director nominees and the accounting firm appointment.